Business
Currency:USD
2024/Q3
Stock NameRevenueRatio
Revenue from anti-CD20 therapeutic programs446.2M18.10%
TYSABRI406.1M16.47%
SPINRAZA381.4M15.47%
Contract manufacturing, royalty and other revenue250.2M10.15%
TECFIDERA232.8M9.44%
Other194.4M7.88%
AVONEX176.2M7.15%
VUMERITY158.1M6.41%
BENEPALI118.1M4.79%
SKYCLARYS102.3M4.15%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
U.S.5.43B55.24%
Europe2.14B21.75%
Germany868M8.83%
Asia863.4M8.78%
Other531.2M5.40%
